CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 501 enrolled
Drug / intervention
Macugendrug
Likely dose
Macugen 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00460408
NCT00460408N/ACompleted
CompareCT.gov

European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe

Pfizer·observational·Posted Apr 16, 2007·Updated Dec 11, 2012

In Brief

An observational study evaluating Macugen for Macular Degeneration. Completed, enrolled 501 participants across 68 sites in 13 countries.

Detailed Summary

The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesBelgium, Cyprus, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Slovakia, Spain, Sweden
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2007
Enrollment StartAug 1, 2006
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 19.2 years ago

Interventions

Macugendrug

Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.